Striking out at disseminated metastases: The systemic delivery of oncolytic viruses

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 4, 2006, Pages 301-313

  Fisher, Kerry ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Bioavailability; Disseminated cancer; Metastasis; Oncolytic virus

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BRADYKININ; CAPSID PROTEIN; CLODRONIC ACID; DOXORUBICIN; FLUOROURACIL; LIPOSOME; ONCOLYTIC VIRUS; ONYX 015; OV 001; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYMER; PV 701; REOLYSIN; RHEOLYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; BLOOD CELL; BLOOD COMPONENT; CANCER CELL; CANCER THERAPY; CELL INTERACTION; CHEMICAL MODIFICATION; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED CANCER; DNA MODIFICATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENETIC MANIPULATION; GENETIC VARIABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CLEARANCE; METASTASIS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARTICLE SIZE; PICORNAVIRUS; PROTEIN INTERACTION; RECEPTOR BINDING; REOVIRUS; REVIEW; SENECA VALLEY VIRUS; SPECIES DIFFERENCE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

HUMANS; NEOPLASM METASTASIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

ANIMALIA;

EID: 33747519945     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Heise CC, Williams AM, Xue S, Propst M, Kirn DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res (1999) 59(11):2623-2628.
2. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 61(24):8751-8757.
3. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M, Shamamian P, Jin R, Novick RP, Pellicer A, Meruelo D: Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol (2004) 22(1):70-77.
4. Shen BH, Bauzon M, Hermiston TW. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther (2006) 13(12):986-990.
5. Parkins CS, Stratford MR, Dennis MF, Stubbs M, Chaplin DJ: The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer (1997) 75(3):319-323.
6. Ilangovan G, Li H, Zweier JL, Kuppusamy P: In vivo measurement of tumor redox environment using EPR spectroscopy. Mol Cell Biochem (2002) 234-235(1-2):393-398.
7. Wu JT, Kirn DH, Wein LM: Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol (2004) 66(4):605-625.
8. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther (2003) 10(5):341-352.
9. Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS, Groene WS, Bamat MK: Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther (2003) 5(6):618-624.
10. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther (2001) 8(10):746-759.
11. Oliver CJ, Shortridge KF, Belyavin G: Diffusion coefficient and molecular weight of type 5 adenovirus by photon-correlation spectroscopy. Biochim Biophys Acta (1976) 437(2):589-598.
12. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 46(12 Pt 1):6387-6392.
13. Oku N, Namba Y: Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol (2005) 391:145-162.
14. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 10(3):255-261.
15. Jain RK, Gerlowski LE: Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol (1986) 5(2):115-170.
16. Mollica F, Jain RK, Netti PA: A model for temporal heterogeneities of tumor blood flow. Microvasc Res (2003) 65(1):56-60.
17. Davison E, Kirby I, Whitehouse J, Hart I, Marshall JF, Santis G: Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med (2001) 3(6):550-559.
18. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W: Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther (1999) 6(9):1520-1535.
19. Excoffon KJ, Hruska-Hageman A, Klotz M, Traver GL, Zabner J: A role for the PDZ-binding domain of the coxsackie B virus and adenovirus receptor (CAR) in cell adhesion and growth. J Cell Sci (2004) 117(Pt 19):4401-4409.
20. Smith TA, Idamakanti N, Rollence, ML, Marshall-Neff J, Kim J, Mulgrew K, Nemerow GR, Kaleko M, Stevenson SC: Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther (2003) 14(8):777-787.
21. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, Nicklin SA, Stevenson SC, Baker AH: Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther (2004) 10(2):344-354.
22. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A: Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 79(12):7478-7491.
23. Ye X, Jerebtsova M, Ray PE: Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther(2000) 11(4):621-627.
24. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 8(1):37-44.
25. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG: Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol (1997) 71(1):624-629.
26. Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, Dries V, Varga G, Van Rooijen N, Kochanek S: A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther(2003) 14(17):1631-1641.
27. Rothkopf C, Fahr A, Fricker G, Scherphof GL, Kamps JA: Uptake of phosphatidylserine-containing liposomes by liver sinusoidal endothelial cells in the serum-free perfused rat liver. Biochim Biophys Acta (2005) 1668(1):10-16.
28. Peiser L, Mukhopadhyay S, Gordon S: Scavenger receptors in innate immunity. Curr Opin Immunol (2002) 14(1):123-128.
29. Rahman YE, Cerny EA, Patel KR, Lau EH, Wright BJ: Differential uptake of liposomes varying in size and lipid composition by parenchymal and kupffer cells of mouse liver. Life Sci (1982) 31(19):2061-2071.
30. Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M, Takakura Y, Hashida M: Hepatic uptake of polystyrene microspheres in rats: Effect of particle size on intrahepatic distribution. J Control Release (1999) 59(1):15-22.
31. Lievens J, Snoeys J, Vekemans K, Van Linthout S, de Zanger R, Collen D, Wisse E, De Geest B: The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther (2004) 11(20):1523-1531.
32. Stehle G, Wunder A, Sinn H, Schrenk HH, Friedrich EA, Dempfle CE, Maier-Borst W, Heene DL: Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats. J Surg Res (1995) 58(2):197-204.
33. Laccotripe M, Makrides SC, Jonas A, Zannis VI: The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high-density lipoprotein. J Biol Chem (1997) 272(28):17511-17522.
34. Liu F, Liu D: Serum independent liposome uptake by mouse liver. Biochim Biophys Acta (1996) 1278(1):5-11.
35. Stolnik S, Heald CR, Neal J, Garnett MC, Davis SS, Illum L, Purkis SC, Barlow RJ, Gellert PR: Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: Production, colloidal properties and biological performance. J Drug Target (2001) 9(5):361-378.
36. Bowie AG, Haga IR: The role of Toll-like receptors in the host response to viruses. Mol Immunol (2005) 42(8):859-867.
37. Chen Y, Yu DC, Charlton D, Henderson DR: Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther (2000) 11(11):1553-1567.
38. Vamavski AN, Calcedo R, Bove M, Gao G, Wilson JM: Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther (2005) 12(5):427-436.
39. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 74(10):4765-4775.
40. Friedman HM, Wang L, Fishman NO, Lambris JD, Eisenberg RJ, Cohen GH, Lubinski J: Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol (1996) 70(7):4253-4260.
41. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A: Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther (2004) 10(6):1140-1142.
42. Lyons M, Onion D, Green NK, Asian K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW et al: Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Molecular Therapy (2006): Epub ahead of print.
43. Nardin A, Lindorfer MA, Taylor RP: How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol (1999) 36(13-14):827-835.
44. Bruns H: Electron microscopic studies of herpes simplex virus type 1 infection of macrophages, T- and B-lymphocytes of mice. Arch Virol (1980) 64(3):257-268.
45. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R: Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J (2004) 1:10.
46. Kristoffersen AK, Sindre H, Mandi Y, Rollag H, Degre M: Effect of adenovirus 2 on cellular gene activation in blood-derived monocytes and macrophages. APMIS (1997) 105(5):402-409.
47. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ: The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther (2002) 13(1):129-141.
48. Hodges BL, Taylor KM, Chu Q, Scull SE, Serriello RG, Anderson SC, Wang F, Scheule RK: Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver. Mol Ther (2005) 12(6):1043-1051.
49. Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, Davidson A, Ott M, Horwitz MS, Chowdhury JR: Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology (1998) 27(5):1368-1376.
50. Geoerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR et al: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med (2005) 7(5):584-594.
51. Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL, Aldrich WA, Banerjee PT, Gillies SD, Curiel DT et al: Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 77(21):11367-11377.
52. Oh KS, Engler JA, Joung I: Enhancement of gene delivery to cancer cells by a retargeted adenovirus. J Microbiol (2005) 43(2):179-182.
53. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E: Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther (2003) 8(3):485-494.
54. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N, Ueber A: A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 9(4):496-509.
55. Volk AL, Rivera AA, Kanerva A, Bauerschmitz G, Dmitriev I, Nettelbeck DM, Curiel DT: Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 2(5):511-515.
56. Shayakhmetov DM, Li ZY, Ni S, Lieber A: Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 78(10):5368-5381.
57. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA et al: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 441(7090):239-243.
58. Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D: Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther (2002) 13(2):311-320.
59. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG et al: Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 174(11):7179-7185.
60. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA: Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol (2003) 77(19):10366-10375.
61. Gahery-Segard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, Boulanger P, Guillet JG: Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 72(3):2388-2397.
62. Wohlfart CE, Svensson UK, Everitt E: Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J Virol (1985) 56(3):896-903.
63. Watson G, Burdon MG, Russell WC: An antigenic analysis of the adenovirus type 2 fibre polypeptide. J Gen Virol (1988) 69(Pt 3):525-535.
64. Hallenbeck P: Novel picornavirus vectors. Third International Meeting on Replicating Oncolytic Virus Therapeutics, Banff, USA (2005).
65. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL: Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA (1998) 95(13):7544-7549.
66. Kremer EJ, Boutin S, Chillon M, Danos O: Canine adenovirus vectors: An alternative for adenovirus-mediated gene transfer. J Virol (2000) 74(1):505-512.
67. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol (1997) 71(11):8798-8807.
68. Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S: Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther (2003) 7(1):35-43.
69. Nomura T, Inamura T, Black KL: Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res (1994) 659(1-2):62-66.
70. Rainov NG, Ikeda K, Qureshi NH, Grover S, Herrlinger U, Pechan P, Chiocca EA, Breakefield XO, Barnett FH: Intraarteriall delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther (1999) 10(2):311-318.
71. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, Muller J, Byrnes AP: Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther (2006) 13(1):108-117.
72. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 3(1):28-35.
73. Albertsson PA, Basso PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ: NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity. Trends Immunol (2003) 24(11):603-609.
74. Varney ML, Johansson SL, Singh RK: Tumour-associated macrophage infiltration, neovascularizartion and aggressiveness in malignant melanoma: Role of monocyte chemotactic protein-1 and vascular endotheliall growth factor-A. Melanoma Res (2005) 16(5):417-425.
75. Demeter K, Zadori A, Agoston VA, Madarasz E: Studies on the use of NE-4C embryonic nouroectodermal stem cells for targeting brain tumour. Neurosci Res (2005) 53(3):331-342.
76. Dobbelstein M: Viruses in therapy - royal road or dead end? Virus Res (2003) 92(2):219-221.
77. Thorne SH, Negrin RS, Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311(5768):1780-1784.
78. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, Brunn G, Thompson J, Chester J, Vile RG: Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med (2005) 11(10):1073-1081.
79. Chillon M, Lee JH, Fasbender A, Welsh MJ: Adenovirurs complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther (1998) 5(7):995-1002.
80. Matthews C, Jenkins G, Hilfinger J, Davidson B: Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther (1999) 6(9):1558-1564.
81. Pearce OM, Fisher KD, Humphries J, Seymour LW, Smith A, Davis BG: Glycoviruses: Chemical glycosylation retargets adenoviral gene transfer. Angew Chem Int Ed Engl (2005) 44(7):1057-1061.
82. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 8(5):341-348.
83. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther (1999) 10(8):1349-1358.
84. Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 81(Pt 11):2605-2609.
85. Mok H, Palmer DJ, Ng P, Barry MA: Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 11(1):66-79.
86. Nakano MY, Boucke K, Suomalainen M, Stidwill RP, Greber UF: The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol. J Virol (2000) 74(15):7085-7095.
87. Awasthi VD, Garcia D, Goins BA, Phillips WT: Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm (2003) 253(1-2):121-132.
88. Mori A, Klibanov AL, Torchilin VP, Huang L: Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett (1991) 284(2):263-266.
89. Henderson YC, Liu TJ, Clayman GL: A simple and sensitive method for detecting adenovirus in serum and urine. J Virol Methods (1998) 71(1):51-56.
90. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther (2004) 11(16):1256-1263.
91. Croyle MA, Chirmule N, Zhang Y, Wilson JM: "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol (2001) 75(10):4792-4801.
92. Perez AT, Domenech GH, Frankel C, Vogel CL: Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: The Cancer Research Network Inc experience. Cancer Invest (2002) 20(Suppl 2): 22-29.
93. Everts M, Curiel DT: Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 4(3):337-346.
94. Wickham TJ: Targeting adenovirus. Gene Ther (2000) 7(2):110-114.
95. Wagner E, Culmsee C, Boeckle S: Targeting of polyplexes: Toward synthetic virus vector systems. Adv Genet (2005) 53:333-354.
96. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 55(18):3964-3968.
97. Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, Delpech B, Lu H: Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer (1996) 66(5):664-668.
98. Eliaz RE, Szoka FC Jr: Liposome-encapsulated doxorubicin targeted to CD44, A strategy to kill CD44-overexpressing tumor cells. Cancer Res (2001) 61(6):2592-2601.
99. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panel A, Libson E, Irving CS et al: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2006) 13(1):221-228.
100. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther (2001) 8(21):1618-1626.
101. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF: Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol (2003) 21(8):1498-1504.
102. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kim D: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 62(21):6070-6079.
103. Vidal L, Pandha H, Spicer J, Harrington KJ, Allen S, Leader D, Coffey M, Thompson B, Kaye S, De-Bono J: A phase I study of reolysin given intravenously to patients with advanced malignancies. J Clin Oncol (2006) 24(18S): Abs 3064